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Background. Combination antiretroviral therapy (cART) has progressively decreased mortality of HIV-associated tuberculosis .To
date, however, limited data on tuberculosis treatment outcomes among coinfected patients who are not ART-naive at the time of
tuberculosis diagnosis are available. Methods. A multicenter, observational study enrolled 246 HIV-infected patients diagnosed
with tuberculosis, in 96 Italian infectious diseases hospital units, who started tuberculosis treatment. A polytomous logistic
regressionmodel was used to identify baseline factors associated with the outcome. A Poisson regressionmodel was used to explain
the eﬀect of ART during tuberculosis treatment on mortality, as a time-varying covariate, adjusting for baseline characteristics.
Results. Outcomes of tuberculosis treatment were as follows: 130 (52.8%) were successfully treated, 36 (14.6%) patients died in a
median time of 2 months (range: 0–16), and 80 (32.6%) had an unsuccessful outcome. Being foreign born or injecting drug users
was associated with unsuccessful outcomes. In multivariable Poisson regression, cART during tuberculosis treatment decreased
the risk of death, while this risk increased for those who were not ART-naive at tuberculosis diagnosis. Conclusions. ART during
tuberculosis treatment is associated with a substantial reduction of death rate among HIV-infected patients. However, patients
who are not ART-naive when they develop tuberculosis remain at elevated risk of death.
1. Introduction
The wider access to combined antiretroviral therapy (cART)
had a profound impact on HIV-associated tuberculosis.
Prospective studies conducted in high-burden and low-
burden countries have clearly shown that incidence of tuber-
culosis is strikingly reduced in persons receiving cART [1–5],
and more recently a randomized trial has shown that early
initiation of cARTwas associated with a significant reduction
of the incidence of extra pulmonary tuberculosis [6]. Nev-
ertheless, incidence of tuberculosis may remain higher than
that observed in non-HIV-infected persons even in cART
treated patients [2, 7].
A number of observational studies have also demon-
strated that starting cART during treatment for tuberculosis
reduces mortality in ART-naive patients in spite of the
increased risk of immune reconstitution syndrome [8]. The
eﬀect of early initiation of cART in HIV-infected patients
with tuberculosis has been also confirmed in randomized
clinical trials [9, 10].
However, little information is available on the outcome
of tuberculosis occurring in patients who are not ART-naive
at the time of tuberculosis diagnosis.
In amulticenter study conducted in Italy in the context of
wide availability of cART, we found that more than one-third
of cases of HIV-associated tuberculosis occurred in patients
2 Clinical and Developmental Immunology
who were already on antiretroviral treatment [11]. In this
paper we analyze the outcome of treatment of tuberculosis
among patients enrolled in that study.
2. Patients and Methods
2.1. Study Design and Subjects Selection. Design of this mul-
ticenter, prospective, observational study has been previously
described [11]. Briefly, 154 Italian infectious diseases hospital
units were invited to participate in the study and 96 (62,3%)
agreed to enroll patients. These units are located in 18 of
Italy’s 20 regions, and all of them are located in public hos-
pital and specialize in HIV care.
Individuals (in and out-patients) 18 years of age or older,
with confirmed HIV infection, diagnosed with tuberculosis
in the participating units during a 15-month period, were
included in the study. All patients were given an identifica-
tion code to guarantee confidentiality and each of the par-
ticipating centers sought ethical clearance according to local
regulations.
2.2. Data Collection. At baseline, the following data were
collected for each enrolled subject: age, sex, country of birth,
place of residence, education, employment, date of first posi-
tive HIV test, mode of HIV infection, history of active tuber-
culosis, results of chest radiographs and clinical evaluation
and microbiological examinations for mycobacterial infec-
tion and disease. Data on concomitant AIDS defining dis-
eases, CD4+ lymphocyte count and current and/or previous
antiretroviral therapy were also recorded. Followup data
were obtained from hospital wards and outpatient clinic
records, and included information on antiretroviral therapy,
tuberculosis treatment outcome, and vital status at the end
of the study period.
All data were collected onto coded standardised forms.
All forms were checked by scientific staﬀ at the coordinating
center for logical errors.
Cultures for mycobateria were performed on radiometric
method (BACTEC; Becton Dickinson, Microbiology Sys-
tems, Sparks, MD, USA) and/or Lo¨wenstein-Jensen medium.
2.3. Definitions and Outcome Variables. A case of tubercu-
losis was defined as a physician diagnosis of tuberculosis in
a person who has bacteriological evidence of active disease
(isolation of Mycobacterium tuberculosis from a clinical
specimen and/or demonstration of M. tuberculosis from a
clinical specimen by nucleic acid amplification) and/or signs
and symptoms compatible with tuberculosis (e.g., an abnor-
mal, unstable chest radiographs, or clinical evidence of cur-
rent disease), completed diagnostic evaluation and decision
by physician to treat with a full course of antituberculosis
chemotherapy. On the basis of microbiological, clinical, radi-
ological or histological findings, tuberculosis was classified
as pulmonary, both pulmonary and extra pulmonary, extra
pulmonary only.
A new case of tuberculosis was defined as a patient who
has never had treatment for tuberculosis, or who has taken
antituberculosis drugs for less than one month. Previously
treated cases were defined as patient who had received at
least 1 month of antituberculous therapy in the past. Drug-
resistant (DR) tuberculosis was defined as caused by a
M. tuberculosis strain resistant to one or more first-line
antituberculosis drugs but not to both isoniazid and rifam-
pin, while multidrug-resistant (MDR) tuberculosis included
cases resistant to at least both. Patients were defined aware
of HIV serostatus if patients they had their first HIV positive
test performed al least 3 months before tuberculosis diagno-
sis.
For the purpose of the present analysis, patients were
defined ART-naive if they had never received antiretrovirals
or they received antiretrovirals for less than one month
before diagnosis of tuberculosis. Patients were defined on
ART at the time of tuberculosis diagnosis if they received
antiretrovirals for at least one month in the three months
preceding tuberculosis diagnosis.
Tuberculosis treatment outcomes were defined according
WHO definitions [12]. For the purpose of the analysis, out-
comes were also grouped in successful outcome (including
patients cured and with completed treatment) and un-
successful outcome (including patients transferred out,
defaulted and treatment failure).
2.4. Statistical Analysis. Descriptive statistical methods were
used to provide a general profile of the study population.
The χ2 or Fisher’s Exact Test, as appropriate, were used to
compare proportions. Odds ratios (ORs) with the associated
95% confidence intervals (CI) were calculated to measure
the association between variables and treatment outcome.
By fitting a polytomous logistic regression, we analyzed asso-
ciation of baseline characteristics associated with death and
unsuccessful outcome of tuberculosis treatment, compared
to successful outcome.
To investigate the impact of cART on mortality rate, a
Poisson regression model was used. Results of this analysis
are presented as mortality rate ratios (MRRs) with the asso-
ciated 95% CI. Patients were included from the initiation
of antituberculosis treatment until completion of treatment,
death or loss to followup, whichever comes first; cART was
included in the analysis as a time-dependent variable to-
gether with potential confounders. Analyses were performed
with STATA software (Stata Corp. Stata Statistical Software.
College Station, TX, USA).
3. Results
3.1. Study Population. We considered for inclusion in the
analysis 271 HIV-infected patients with who were diagnosed
with tuberculosis during the study period. Among these
patients, 25 (9.22%) did not start tuberculosis treatment, 5
because they were transferred-out and 20 who were lost to
follow up immediately after diagnosis. The remaining 246
patients entered the present analysis.
Table 1 shows characteristics of patients at tuberculosis
diagnosis. The majority of patients (80.2%) were males and
the median age was 36.9 (range 21.27–76.03) years. Diagno-
sis of tuberculosis was confirmed by culture in 160 patients
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Table 1: Characteristics of 246 HIV-infected patients at tuberculosis diagnosis and outcome of treatment.
Variable n (%)
Successful outcome
n (%)
Death
n (%)
Unsuccessful outcome
n (%)
P value
Sex
Male 199 97 (48.7) 32 (16.1) 70 (35.2) 0.035
Female 47 33 (70.2) 4 (8.5) 10 (21.3)
Place of origin
Born in Italy 162 84 (51.9) 29 (17.9) 49 (30.2) 0.11
Foreign born 84 46 (54.8) 7 (8.3) 31 (36.9)
Age at TB diagnosis (years)
<40 162 87 (53.7) 18 (11.1) 57 (35.2) 0.084
≥40 84 43 (51.2) 18 (21.4) 23 (27.4)
Education (years)
0–8 146 75 (51.4) 21 (14.4) 50 (34.2) 0.850
9–18 51 26 (51.0) 9 (17.6) 16 (31.4)
Unknown 49 29 (59.2) 6 (12.2) 14 (28.6)
History of imprisonment
Yes 24 12 (50.0) 4 (16.7) 8 (33.3) 0.91
No/unknown 222 118 (53.2) 32 (14.4) 72 (32.4)
Mode of HIV infection
Injecting drug use 119 49 (41.2) 25 (21.0) 45 (37.8) 0.001
Other 127 81 (63.8) 11 (8.7) 35 (27.6)
Housing
Private 209 116 (55.5) 33 (15.8) 60 (28.7) 0.014
Community/homeless 37 14 (37.8) 3 (8.1) 20 (54.1)
CD4 lymphocyte count (cells/mmc)
0–199 156 81 (51.9) 26 (16.7) 49 (31.4) 0.18
200–350 42 20 (47.6) 8 (19.0) 14 (33.3)
>350 48 29 (60.4) 2 (4.2) 17 (35.4)
AIDS
Yes 132 65 (49.2) 27 (20.5) 40 (30.3) 0.019
No 114 65 (57.0) 9 (7.9) 40 (35.1)
Site of diseases
Pulmonary 197 101 (51.3) 28 (14.2) 68 (34.5) 0.413
Extra pulmonary 49 29 (59.2) 8 (16.3) 12 (24.5)
History of TB treatment
New cases 206 113 (54.9) 28 (13.6) 65 (31.6) 0.279
Previously treated cases 40 17 (42.5) 8 (20.0) 15 (37.5)
Drug susceptibility test#
Susceptible TB 99 54 (54.5) 15 (15.2) 30 (30.3) 0.387
DRTB 22 13 (59.1) 2 (9.1) 7 (31.8)
MDR TB 4 1 (25.0) 2 (50.0) 1 (25.0)
Awareness of HIV seropositivity
Yes 176 79 (44.9) 31 (17.6) 66 (37.5) <0.001
No 70 51 (72.9) 5 (7.1) 14 (20.0)
cART naive
Yes 150 84 (56.0) 16 (10.7) 50 (33.3) 0.091
No 96 46 (47.9) 20 (20.8) 30 (31.2)
Concomitant diseases at TB diagnosis
Yes 60 30 (50.0) 15 (25.0) 15 (25.0) 0.033
No 186 100 (53.8) 21 (11.3) 65 (34.9)
#
Calculated on 125 patients with drug susceptibility test performed.
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(74,7%); 125 patients had results of antimycobacterial drugs
susceptibility testing, of whom 22 (17.6%) had drug-resistant
tuberculosis and 4 (3.2%) multidrug-resistant tuberculosis.
The median time from first date of documented HIV
seropositivity was 36.9 months (range: 0–201.3), and 96
(39%) were not ART-naive at the time of tuberculosis diag-
nosis. Of these patients, 34 received antiretroviral therapy for
a median of 13.5 months (range 1–86), but not in the three
months preceding diagnosis of tuberculosis, and their last
ART regimen included a protease inhibitor (PI) in 20 patients
and a nonnucleoside reverse transcriptase inhibitor (NNRTI)
in 11 patients.
At baseline the median value of CD4 lymphocytes was
120.5/mmc (range 0–1111), and viral load median value, cal-
culated in 241 patients, was 4.94 log copies/mL. At least one
concomitant AIDS defining illness disease was recorded in 60
(24.4%) patients.
3.2. Tuberculosis Treatment Outcome. We recorded tubercu-
losis treatment outcomes for the 246 patients included in
the analysis. A successful outcome was recorded for 130
patients (52.8%), among them 75 (30.5%) were cured and 55
(22.4%) completed treatment. Eighty patients (32.5%) had
unsuccessful outcomes: 44 (17.9%) were lost to follow up in
a median time of 1 month, and 25 (10.2%) were defaulters,
9 (3.7%) were transferred-out, and 2 (0.8%) were failures.
Thirty-six patients (14.6%) died a median time of 2 months
after tuberculosis treatment initiation.
Table 1 shows the distribution of treatment outcomes ac-
cording to baseline patients’ characteristics.
In multivariable polytomous logistic regression analysis
(Table 2), not being ART-naive was associated with an in-
crease of the probability of unsuccessful outcomes. Being
foreign born was associated with a threefold increase of the
risk of unsuccessful outcomes (OR 3.38, 95% CI 1.38–8.29,
P = 0.008), which was also more likely for injecting drug
users. Risk of death was also associated with being injecting
drug users as well as to a lower CD4 cells count at the time of
tuberculosis diagnosis and MDR tuberculosis.
3.3. Use of cART during Tuberculosis Treatment and Risk of
Death. Among the patients enrolled, 151 (61.4%) received
cART and tuberculosis treatment concurrently. Of these
patients 62 were already on cART when tuberculosis was
diagnosed and 89 started cART during tuberculosis treat-
ment, 56 (62.9%) in the initial phase and 33 (37.1%) in the
continuation phase and included a PI in. Patients who were
already on cART at initiation of TB have been receiving anti-
retrovirals for a median of 24 months (range 3–108) before
diagnosis of tuberculosis and their last cART regimen in-
cluded a PI in 35 cases and an NNRTI in 23. An additional 21
patients were not ART-naive but not on ART at tuberculosis
diagnosis. ART administered during tuberculosis treatment
included a PI in 75 cases (49.7%).
We performed a further analysis in order to estimate
the impact of use of cART during tuberculosis treatment on
death rate of HIV-infected patients with tuberculosis.
During 161.2 person-years (PY) of observation, 36
deaths occurred with an overall mortality rate of 22.3 per
100 PY (95% CI: 16.1–31.0). Among the patients who died,
17 were not ART-naive, 7 were ART-naive and started cART
during tuberculosis treatment and 12 patients never started
cART.
In multivariable analysis (Table 3), the use of cART
during tuberculosis treatment significantly reduced the risk
of death (IRR 0.14, 95% CI 0.06–0.30, P < 0.001), whereas
being not ART-naive at tuberculosis diagnosis caused a more
than four-fold increase in the same risk (IRR 4.04, 95% CI
1.09–14.96, P = 0.037). Risk of death was also associated
with a lower CD4 cell count, age≥ 40 at diagnosis, andMDR
tuberculosis.
4. Discussion
In this multicentre study conducted in a low tuberculosis
incidence country, a successful outcome of tuberculosis
treatment was documented in slightly more than 50% of
HIV-infected patients; the death of the patient during treat-
ment was recorded in almost 15% patients. When we an-
alyzed the impact of cART before and during tuberculosis
treatment on the risk of death, we found the cART use during
tuberculosis treatment reduced the probability of dying,
while this risk was increased in those who were not ART-
naive at tuberculosis diagnosis.
The overall success rate of tuberculosis treatment ob-
served in the present study is lower than that reported in
other European studies in general population. A survey con-
ducted in 10 European countries [13] found an overall pro-
portion of successful outcome of tuberculosis treatment
of 69% with a range between 60% and 88% in diﬀerent
countries and a death rate of 1%. In a systematic review of
European surveys [14], an overall success rate of 74.4% was
recorded with a death rate of 6.9%. These discrepancies how-
ever were not unexpected. First of all a high proportion of
patients in our study population were intravenous drug users
(48%) or foreign born (34%), and both these characteristics
have been associated with a greatly reduced probability of
successful outcome of tuberculosis treatment. For example
in a Spanish study [15] intravenous drug users and foreign
born persons had a six-fold or higher increase of the risk of
interrupting treatment. This association was observed also in
our analysis, in which the death outcome was alsomore likely
for intravenous drug users.
However, the main diﬀerence with surveys of tuberculo-
sis treatment outcome in general population is the increased
proportion of death, and HIV infection per se may most
likely account for the observed discrepancies in death rates.
Indeed the above-referenced Spanish multicentre survey [15]
found a six-fold increase in death rate among HIV-infected
patients with tuberculosis compared to non-HIV infected
patients.
We further explored the association between the risk
of death and the use of cART. In our study population,
almost 50% of patients continued or started cART during the
initiation phase of tuberculosis treatment and an additional
14% initiated cART during the continuation phase. Overall,
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Table 2: Multivariable odds ratios∗ of unsuccessful outcome of tuberculosis treatment and death according to baseline characteristics for
246 HIV-infected patients with tuberculosis.
Variable
Unsatisfactory outcome of TB treatment Death
OR (95% CI) P value OR (95% CI) P value
Sex
Male 1.00 1.00
Female 0.38 (0.16–0.90) 0.029 0.35 (0.10–1.27) 0.112
Place of origin
Born in Italy 1.00 1.00
Foreign born 3.66 (1.48–9.06) 0.005 1.98 (0.52–7.45) 0.314
Age at TB diagnosis (years)
<40 1.00 1.00
≥40 1.04 (0.52–2.11) 0.909 2.34 (0.94–5.84) 0.068
Education (years)
0–8 1.00 1.00
9–18 1.00 (0.44–2.27) 0.996 0.81 (0.27–2.37) 0.698
Unknown 0.83 (0.35–1.96) 0.671 0.69 (0.20–2.35) 0.550
History of imprisonment
Yes 1.00 1.00
No/unknown 1.93 (0.65–5.74) 0.238 2.17 (0.53–8.90) 0.282
Mode of HIV infection
Injecting drug use 1.00 1.00
Other 0.42 (0.19–0.93) 0.033 0.25 (0.08–0.74) 0.012
Housing
Private 1.00 1.00
Community/homeless 2.21 (0.93–5.30) 0.074 0.44 (0.09–2.30) 0.333
CD4 lymphocyte count (increase: 50 cells) 0.96 (0.88–1.04) 0.326 0.83 (0.71–0.97) 0.020
AIDS
Yes 1.00 1.00
No 0.90 (0.45–1.82) 0.778 0.44 (0.16–1.19) 0.106
Site of diseases
Pulmonary 1.00 1.00
Extra pulmonary 0.66 (0.29–1.50) 0.320 1.15 (0.42–3.18) 0.782
History of TB treatment
New cases 1.00 1.00
Previously treated cases 0.96 (0.39–2.36) 0.930 0.71 (0.22–2.32) 0.572
Drug susceptibility test
Susceptible TB 1.00 1.00
DR TB 1.03 (0.33–3.21) 0.962 0.44 (0.07–2.69) 0.376
MDR TB 0.83 (0.03–20.52) 0.911 37.10 (1.98–693.79) 0.016
Not available 1.41 (0.71–2.78) 0.322 1.24 (0.50–3.07) 0.649
Awareness of HIV seropositivity and HIV
treatment history
Not aware 1.00 1.00
Aware and cART naive 5.11 (2.04–12.80) 0.001 2.95 (0.77–11.33) 0.115
Not cART naive 3.31 (1.29–8.46) 0.013 4.04 (1.09–14.96) 0.037
Concomitant diseases at TB diagnosis
Yes 1.00 1.00
No 1.38 (0.59–3.26) 0.461 0.59 (0.23–1.55) 0.286
∗
From polytomous logistic regression model with successful outcome as reference category.
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Table 3: Univariable and multivariable mortality rate ratio (MRR)∗ for 246 HIV-infected patients with tuberculosis.
Variable
Univariable analysis Multivariable analysis
MRR (95% CI) P value MRR (95% CI) P value
Sex
Male 1.00 1.00
Female 0.52 (0.18–1.47) 0.217 0.46 (0.15–1.38) 0.163
Place of origin
Born in Italy 1.00 1.00
Foreign born 0.50 (0.22–1.15) 0.102 1.36 (0.42–4.41) 0.608
Age at TB diagnosis
<40 1.00 1.00
≥40 1.96 (1.02–3.77) 0.043 2.73 (1.26–5.93) 0.011
Education (years)
0–8 1.00 1.00
9–18 1.14 (0.52–2.50) 0.736 0.92 (0.39–2.21) 0.855
Unknown 0.81 (0.33–2.02) 0.659 1.00 (0.36–2.76) 0.999
History of imprisonment
Yes 1.00 1.00
No/unknown 0.80 (0.28–2.26) 0.675 2.05 (0.64–6.60) 0.282
Mode of HIV infection
IDU 1.00 1.00
Other 0.37 (0.18–0.75) 0.006 0.39 (0.15–0.99) 0.047
Housing
Private 1.00 1.00
Community/homeless 0.71 (0.22–2.32) 0.573 0.29 (0.07–1.17) 0.082
CD4 lymphocyte count (per 50 cells increase) 0.85 (0.75–0.96) 0.010 0.83 (0.72–0.95) 0.006
AIDS
Yes 1.00 1.00
No 0.40 (0.19–0.85) 0.017 0.47 (0.20–1.13) 0.091
Site of diseases
Pulmonary 1.00 1.00
Extra pulmonary 0.94 (0.43–2.07) 0.888 1.36 (0.59–3.11) 0.471
History of TB treatment
New cases 1.00 1.00
Previously treated cases 1.53 (0.70–3.35) 0.292 0.78 (0.32–1.94) 0.597
Drug susceptibility test
Susceptible TB 1.00 1.00
DR TB 0.48 (0.11–2.12) 0.336 0.34 (0.07–1.68) 0.184
MDR TB 3.91 (0.90–17.12) 0.070 35.50 (5.50–229.19) <0.001
Not available 0.85 (0.43–1.71) 0.658 1.34 (0.60–3.00) 0.471
Awareness of HIV seropositivity and HIV
treatment history
Not aware 1.00 1.00
Aware and ART-naive 2.64 (0.92–7.60) 0.072 1.73 (0.52–5.72) 0.370
Not ART-naive 3.41 (1.28–9.08) 0.014 4.27 (1.27–14.29) 0.019
cART (time dependent)
No 1.00 1.00
Yes 0.26 (0.13–0.52) <0.001 0.14 (0.06–0.30) <0.001
Concomitant diseases at TB diagnosis
Yes 1.00 1.00
No 0.43 (0.22–0.83) 0.012 0.63 (0.29–1.35) 0.231
∗Estimated by a Poisson regression model.
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the use of cART was associated with a greater than six-fold
reduction of the risk of death. This eﬀect is of the same
order of magnitude of that observed both in high and low
tuberculosis incidence countries [8]. Thus our data concur
with available evidence suggesting the importance of starting
cART early during tuberculosis treatment [16].
A relevant finding was the increased risk of death for
individuals who were not ART-naive when diagnosed with
tuberculosis, which remained significant when we adjusted
in the analysis for current cART use as well as for other fac-
tors associated with the risk of death such as a low CD4 cells
count, older age at tuberculosis diagnosis, and multidrug
resistance. The reasons for this association remains to be
elucidated, nevertheless some hypothesis can be put forward.
First of all, some patients had interrupted cART treatment
before tuberculosis was diagnosed and this may be a marker
of poor adherence to cART or previous cART failure or cART
toxicity. Thus, even if cART is resumed during tuberculosis
treatment, a reduced eﬀect could be expected in these
patients. Moreover, treatment interruptions per se have been
associated with an increased risk of death [17]. Occurrence
of tuberculosis during cART may also be a marker of pro-
gression of HIV disease also when CD4 cell count and HIV
viral load are taken into consideration, and indeed tubercu-
losis in cART-treated patients has been identified as an inde-
pendent predictor of other HIV-associated clinical events
and death [18].
Tuberculosis occurring in cART-treated patients may in
some instances be due to the so-called unmasking, which is
defined as clinical manifestation of preexisting tuberculosis
infection that is due to ART-induced immune restoration
and which may sometimes result in severe or even fatal dis-
ease [19]. We do not have clinical details to evaluate severity
of tuberculosis in our patients. However, tuberculosis un-
masking usually occurs during the first few weeks of cART
[19, 20], while in the present study most of the patients who
were not ART-naive were treated for several months before
tuberculosis diagnosis.
In this study we do not have details of antiretroviral
treatment history of patients and in particular we cannot
determine if those who were not ART-naive had virological
treatment failures and/or antiretroviral resistance at the time
of tuberculosis diagnosis, and thus we could not estimate
the impact of these factors on patients’ outcome. The high
proportion of patients who abandoned treatment may also
have aﬀected the analysis of factors associated with death. A
further limitation is that the study was conducted on patients
treated relatively early in the cART era, and thus the con-
clusions on the eﬀect on cART may not necessarily be appli-
cable to the newer cART regimens.
In conclusion these study shows an alarmingly high pro-
portion of unsuccessful outcome of tuberculosis in HIV-
infected persons who inject drugs or are migrants and
stresses the need of intervention aimed at keeping these pa-
tients into care.
Tuberculosis occurred frequently in patients who were
not ART-naive, and these patients had an increased risk of
death compared to those who were ART-naive, also after
taking into account the use of ART during tuberculosis
treatment. Tuberculosis occurring in patients who already
received ART may represent in the future an important issue
to be addressed in high tuberculosis incidence countries in
which scaling up of ART is currently underway.
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